Imugene Ltd (IMU) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Imugene Ltd (IMU) has a cash flow conversion efficiency ratio of -0.620x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-25.97 Million ≈ $-18.38 Million USD) by net assets (AU$41.87 Million ≈ $29.62 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see IMU stock market capitalisation for the company's overall valuation and market capitalisation.
Imugene Ltd - Cash Flow Conversion Efficiency Trend (1993–2025)
This chart illustrates how Imugene Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Imugene Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Imugene Ltd ranked by their cash flow conversion efficiency. Explore Imugene Ltd cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Great Western Mining Corp Plc
IR:8GW
|
-0.028x |
|
Rathbone Brothers PLC
LSE:RAT
|
0.142x |
|
Greenland Acquisition Corp
NASDAQ:GTEC
|
0.118x |
|
Century Extrusions Limited
NSE:CENTEXT
|
0.095x |
|
Bakrie Sumatera Plantations
JK:UNSP
|
-0.021x |
|
Aberforth Smaller Companies Trust PLC
LSE:ASL
|
0.015x |
|
Vaswani Industries Limited
NSE:VASWANI
|
0.072x |
|
Foxx Development Holdings Inc.
NASDAQ:FOXX
|
-0.030x |
Annual Cash Flow Conversion Efficiency for Imugene Ltd (1993–2025)
The table below shows the annual cash flow conversion efficiency of Imugene Ltd from 1993 to 2025. View today's stock price for Imugene Ltd for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | AU$45.03 Million ≈ $31.86 Million |
AU$-75.57 Million ≈ $-53.47 Million |
-1.678x | -95.07% |
| 2024-06-30 | AU$118.25 Million ≈ $83.67 Million |
AU$-101.73 Million ≈ $-71.98 Million |
-0.860x | -447.78% |
| 2023-06-30 | AU$189.63 Million ≈ $134.17 Million |
AU$-29.78 Million ≈ $-21.07 Million |
-0.157x | +28.98% |
| 2022-06-30 | AU$138.70 Million ≈ $98.14 Million |
AU$-30.67 Million ≈ $-21.70 Million |
-0.221x | -9.50% |
| 2021-06-30 | AU$65.02 Million ≈ $46.00 Million |
AU$-13.13 Million ≈ $-9.29 Million |
-0.202x | -19.19% |
| 2020-06-30 | AU$59.81 Million ≈ $42.32 Million |
AU$-10.13 Million ≈ $-7.17 Million |
-0.169x | +41.54% |
| 2019-06-30 | AU$27.29 Million ≈ $19.31 Million |
AU$-7.91 Million ≈ $-5.60 Million |
-0.290x | +0.52% |
| 2018-06-30 | AU$15.48 Million ≈ $10.95 Million |
AU$-4.51 Million ≈ $-3.19 Million |
-0.291x | -24.18% |
| 2017-06-30 | AU$11.39 Million ≈ $8.06 Million |
AU$-2.67 Million ≈ $-1.89 Million |
-0.235x | +39.56% |
| 2016-06-30 | AU$7.86 Million ≈ $5.56 Million |
AU$-3.05 Million ≈ $-2.16 Million |
-0.388x | -46.86% |
| 2015-06-30 | AU$7.73 Million ≈ $5.47 Million |
AU$-2.04 Million ≈ $-1.45 Million |
-0.264x | -55.52% |
| 2014-06-30 | AU$6.73 Million ≈ $4.76 Million |
AU$-1.14 Million ≈ $-809.52K |
-0.170x | +76.58% |
| 2013-06-30 | AU$1.89 Million ≈ $1.33 Million |
AU$-1.37 Million ≈ $-968.40K |
-0.726x | +19.38% |
| 2012-06-30 | AU$1.07 Million ≈ $759.51K |
AU$-965.92K ≈ $-683.45K |
-0.900x | -447.17% |
| 2011-06-30 | AU$4.21 Million ≈ $2.98 Million |
AU$1.09 Million ≈ $771.53K |
0.259x | +156.39% |
| 2010-06-30 | AU$3.79 Million ≈ $2.68 Million |
AU$-1.74 Million ≈ $-1.23 Million |
-0.460x | -377.67% |
| 2009-06-30 | AU$5.33 Million ≈ $3.77 Million |
AU$881.77K ≈ $623.91K |
0.166x | +160.74% |
| 2008-06-30 | AU$4.67 Million ≈ $3.30 Million |
AU$-1.27 Million ≈ $-900.66K |
-0.273x | +24.77% |
| 2007-06-30 | AU$4.70 Million ≈ $3.33 Million |
AU$-1.70 Million ≈ $-1.20 Million |
-0.362x | -27.73% |
| 2006-06-30 | AU$6.46 Million ≈ $4.57 Million |
AU$-1.83 Million ≈ $-1.30 Million |
-0.284x | -50.67% |
| 2005-06-30 | AU$8.65 Million ≈ $6.12 Million |
AU$-1.63 Million ≈ $-1.15 Million |
-0.188x | +32.68% |
| 2004-06-30 | AU$5.43 Million ≈ $3.84 Million |
AU$-1.52 Million ≈ $-1.07 Million |
-0.280x | +71.84% |
| 2002-06-30 | AU$792.83K ≈ $560.98K |
AU$-787.36K ≈ $-557.11K |
-0.993x | -108.81% |
| 2001-06-30 | AU$-226.54K ≈ $-160.29K |
AU$-2.55 Million ≈ $-1.81 Million |
11.266x | +892.20% |
| 2000-06-30 | AU$2.78 Million ≈ $1.97 Million |
AU$-3.95 Million ≈ $-2.80 Million |
-1.422x | -147.09% |
| 1999-06-30 | AU$6.00 Million ≈ $4.24 Million |
AU$-3.45 Million ≈ $-2.44 Million |
-0.576x | -99.40% |
| 1997-06-30 | AU$7.45 Million ≈ $5.27 Million |
AU$-2.15 Million ≈ $-1.52 Million |
-0.289x | -16.06% |
| 1996-06-30 | AU$8.12 Million ≈ $5.75 Million |
AU$-2.02 Million ≈ $-1.43 Million |
-0.249x | -58.27% |
| 1995-06-30 | AU$10.62 Million ≈ $7.52 Million |
AU$-1.67 Million ≈ $-1.18 Million |
-0.157x | -20.81% |
| 1994-06-30 | AU$11.19 Million ≈ $7.91 Million |
AU$-1.46 Million ≈ $-1.03 Million |
-0.130x | -235.76% |
| 1993-06-30 | AU$5.11 Million ≈ $3.62 Million |
AU$-198.00K ≈ $-140.10K |
-0.039x | -- |
About Imugene Ltd
Imugene Limited, a clinical-stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumours in Australia. Its lead products under development azer-cel, an allogeneic CAR T cell therapy in phase 1 clinical trial targeting relapsed/refractory non-hodgkin lymphoma and b-cell acute lymphoblastic leukemia; CF33 VAXINIA,… Read more